Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R.

Hypertension. 2008 Aug;52(2):249-55. doi: 10.1161/HYPERTENSIONAHA.108.113159. Epub 2008 Jul 7.

2.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.

J Am Soc Nephrol. 1998 Aug;9(8):1427-32.

3.

Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.

Moist L, Sontrop JM, Gallo K, Mainra R, Cutler M, Freeman D, House AA.

Am J Kidney Dis. 2010 Oct;56(4):643-50. doi: 10.1053/j.ajkd.2010.03.028. Epub 2010 Jun 11.

PMID:
20541301
4.

Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate.

Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD.

Kidney Int. 2011 Nov;80(10):1073-9. doi: 10.1038/ki.2011.207. Epub 2011 Jun 29.

5.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D.

Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.

PMID:
21055801
6.

Antiproteinuric effect of oral paricalcitol in chronic kidney disease.

Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D.

Kidney Int. 2005 Dec;68(6):2823-8.

7.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
8.

Paricalcitol and endothelial function in chronic kidney disease trial.

Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F.

Hypertension. 2014 Nov;64(5):1005-11. doi: 10.1161/HYPERTENSIONAHA.114.03748. Epub 2014 Aug 4. Erratum in: Hypertension. 2015 Jun;65(6):e48. Hypertension. 2017 Jul;70(1):e1.

9.

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD.

JAMA. 2012 Feb 15;307(7):674-84. doi: 10.1001/jama.2012.120.

PMID:
22337679
10.

Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.

Joergensen C, Tarnow L, Goetze JP, Rossing P.

Diabet Med. 2015 Mar;32(3):374-81. doi: 10.1111/dme.12606. Epub 2014 Nov 5.

PMID:
25307511
11.

Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Larsen T, Mose FH, Bech JN, Pedersen EB.

BMC Nephrol. 2013 Jul 26;14:163. doi: 10.1186/1471-2369-14-163.

12.

Growth hormone treatment in hemodialysis patients--a randomized, double-blind, placebo-controlled study.

Ericsson F, Filho JC, Lindgren BF.

Scand J Urol Nephrol. 2004;38(4):340-7.

PMID:
15669595
13.

Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.

Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S42-7.

14.

Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients.

Ekart R, Bevc S, Hojs R, Hojs N.

J Clin Pharmacol. 2016 Jun;56(6):761-8. doi: 10.1002/jcph.660. Epub 2015 Dec 21.

PMID:
26465921
15.
16.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
17.

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

Miller JE, Molnar MZ, Kovesdy CP, Zaritsky JJ, Streja E, Salusky I, Arah OA, Kalantar-Zadeh K.

Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1232-9. doi: 10.1002/pds.3349. Epub 2012 Sep 20.

18.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
19.

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA.

J Diabetes Complications. 2015 Apr;29(3):433-7. doi: 10.1016/j.jdiacomp.2015.01.004. Epub 2015 Jan 13.

20.

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.

Clin Nephrol. 2001 Oct;56(4):315-23.

PMID:
11680662

Supplemental Content

Support Center